Novartis partners with Brazil's Fiocruz on neglected diseases

28 October 2019
novartis_sign_large

Swiss pharma giant Novartis (NOVN: VX) has signed Memorandum of Understanding with Brazil’s Oswaldo Cruz Foundation (Fiocruz) to formalize the cooperation intention of the two institutions in teaching, research and technological development projects to combat neglected diseases such as Leprosy, Chagas disease, malaria and sickle cell disease.

The partnership 0contemplates the elaboration and joint implementation of initiatives in health research and the academic exchange of researchers and students, in addition to prioritizing the sharing of information and technical documentation, organization of conferences and the publication of scientific articles. The research will be in partnership with clinical centers in Latin America.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical